Tag: cytokinetics

January 7, 2020

Cytokinetics Starts Phase 2 Clinical Trial for Cardiomyopathy Treatment

The company said its myosin inhibitor will be evaluated to optimize its dosing schedule to a therapeutic window for patients...
January 6, 2020

Cytokinetics Announces Start of Phase 2 Clinical Trial of CK-3773274

Cytokinetics announced that REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM) has opened to enrollment.
August 27, 2019

Cytokinetics and Cure SMA Renew Partnership

Cure SMA and Cytokinetics (NASDAQ:CYTK) have renewed their partnership to increase and raise awareness for spinal muscular atrophy (SMA). As...
July 23, 2019

Cytokinetics Granted European Orphan Designation for Reldesemtiv to Treat Spinal Musclar Atrophy

Cytokinetics (NASDAQ:CYTK) has announced that the European Medicines Agency (EMA) has granted the company orphan medicinal product designation to reldesemtiv...
February 20, 2019

Cytokinetics Announces Initiation of Phase 1 Clinical Study of AMG 594, a Cardiac Troponin Activator

Cytokinetics (NASDAQ:CYTK) has announced the first subject has been dosed in a Phase 1 randomized, double-blind, placebo-controlled and multiple ascending...
December 5, 2018

Cytokinetics Announces Initiation of Phase 1 Clinical Trial of CK-3773274

Cytokinetics (Nasdaq:CYTK) announced the first subject has been dosed in a Phase 1 double-blind, randomized, placebo-controlled, multi-part, single and multiple...
October 5, 2018

Cytokinetics and Astellas Provide Updates Regarding Collaborative Skeletal Muscle Program

Cytokinetics (Nasdaq:CYTK) and Astellas Pharma (TSE:4503) today provided an update for their collaborative skeletal muscle program, including clinical trial updates...